B73/100

Is GE HealthCare (GEHC) a risky stock?

Sector: Health Care Price: $62.49 Composite: 73/100

As of July 21, 2026, Clavix grades GE HealthCare (GEHC) B for risk, a composite score of 73 out of 100 on an A+ to F scale, which puts GEHC in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.

Grade as of July 21, 2026. Clavix regrades every trading day.

The five risk dimensions behind GEHC's grade

Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how GEHC scores on each, as of July 21, 2026.

Financial healthbalance sheet, margins, cash flow
61
News sentimentscored, sourced recent coverage
80
Macro exposuresensitivity to rates, dollar, oil
58
Sector resiliencestrength vs the broad market
57
Price stabilitydrawdown and volatility
44

What's moving GEHC's risk right now

Company-specific signals Clavix flags behind GEHC's current grade, drawn from recent news and filings as of July 21, 2026.

Technical setup · supporting the grade

Price structure and relative strength suggest accumulation, which often precedes fundamental re-rating catalysts.

Competition · supporting the grade

The long-term deal provides GEHC with a predictable, multi-year revenue stream and deepens its footprint in the U.S. hospital market, which investors rewarded with a notable stock…

Margins · supporting the grade

This multi-year, large-value contract strengthens GE HealthCare's installed base and recurring revenue visibility in its core U.S. hospital market, with $50M/year average revenue…

What a B grade means

On the Clavix A+ to F scale, GEHC's composite of 73 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.

A+AA-B+BB-C+CC-D+DD-F
Get Clavix on iPhone → Or grade your whole portfolio free, no account needed.

This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell GEHC or any security. Grades are risk indicators, not predictions of return. Data may be delayed.